Moderna stock forecast 2025： MRNA is worth buying for 5 reasons

Moderna was founded in 2009 and was established in Cambridge, Massachusetts, USA. Its main business is genetic engineering and focuses on the research and development of mRNA-derived drugs.

The full name of mRNA is messenger RNA, pre-messenger RNA, a kind of immature single-stranded messenger ribonucleic acid, once it is completely processed, it is called "mature messenger RNA", or "mRNA".

These drugs use mRNA as a treatment method and use mRNA as the basis to inject the developed synthetic mRNA into the patient's body so that the patient's own cells can obtain the ability to treat themselves.

At present, the new crown vaccine being researched and developed by Moderna has an effective rate of 94.5%, so it has become one of the vaccines that are sold in large quantities all over the world.

Cambridge, Massachusetts, is not only home to Harvard University but also a world-renowned hot spot for modern biomedicine.

Despite such a "gorgeous background", Moderna's entrepreneurial road is not smooth.

Between 2010 and 2016, this company carried out a series of research and development for conventional vaccines, in an attempt to occupy this vast market and lucrative field with new vaccines.

However, these R&D and clinical trials have basically failed.

However, in this process of innovation, Modena established a leading position in the mRNA field, which attracted the attention of many pharmaceutical companies.

In 2013, Moderna entered the field of therapeutic vaccines in cooperation with AstraZeneca.

In 2014, Moderna joined forces with Alexion to enter the field of rare diseases.

Unfortunately, these cooperative studies have yet to yield results.

This makes some experts directly question the true reliability of Moderna's technology.

However, the outbreak of the new crown epidemic in 2020 gave Moderna an opportunity.

The effective rate of the new crown vaccine and the recent announcement of the clinical results of their therapeutic tumor vaccine has caused the stock price to rise sharply.

From January 1, 2020, to January 25, 2021, Moderna's stock has risen 690%.

Regarding Moderna's financial situation.

In May of this year, Moderna made a profit for the first time, with revenue of US$1.9 billion in the first quarter, and the new crown vaccine contributed nearly 90%.

Company valuation: it is still at a loss stage, and the price-earnings ratio does not exist;

P/B ratio = 23.01

Price-to-earnings ratio = price per share/earnings per share, it is one of the important indicators to measure whether a stock has investment value.

Under normal circumstances, the lower the price-earnings ratio of a stock, the lower the profitability of the market price relative to the stock, indicating that the shorter the investment payback period, the smaller the investment risk, and the greater the investment value of the stock.

If the price-to-book ratio is negative, it means that the company is still at a loss-making stage, and the risk is high, and it is impossible to predict the payback period of the investment.

PS: The price-to-book ratio refers to the ratio between the market price and the net assets per share. The price-to-book ratio = price per share/net assets per share. The lower the ratio, the lower the risk.

On January 25, 2021, the company's market value was 57.5 billion U.S. dollars, which is a company with a large market value.

Moderna is worth buying mainly for 5 reasons:

First of all, mRNA technology is extremely original, and RNA vaccines have been developed. It is the first to verify that the use of RNA can produce vaccines, and it is difficult for new competitors to replicate in a short period.

Due to the relatively high technical threshold for the development of mRNA vaccines, there is currently no product on the market for mRNA vaccines other than Pfizer, and its industry maturity needs to be improved.

The research and development principle of this type of vaccine is to deliver mRNA carrying the genetic information of the virus's characteristic protein into the cell and activate the immune response through expression in the body, thereby producing effective antibodies.

The process of human immunity with mRNA vaccine mimics the process of virus invasion to a certain extent and can stimulate human cellular and humoral immune responses.

Therefore, mRNA vaccines have multiple advantages such as strong immune activity, short research and development cycle, and suitable for the prevention of sudden infectious diseases, and are considered by the industry to have breakthrough potential.

Second, the product pipeline is rich. In addition to the new crown vaccine that is already on the market, Moderna's research and development line also have 1 phase 3 clinical, 7 phase 2 clinical trials, and 5 phase 1 clinical pharmaceuticals.

Third, the current clinical phase 2 data of the Moderna cytomegalovirus vaccine is good, and it enters clinical phase 3. If successful, it will be the only one on the market.

Fourth, before the outbreak of the new crown epidemic, Moderna's mRNA vaccine has carried out multiple clinical studies in the field of preventive vaccines and therapeutic tumor vaccines, of which the fastest progress is still in the phase II clinical trial stage.

Therefore, in addition to the vaccine field, RNA technology is also at the forefront of cancer immunotherapy, especially drugs for ovarian cancer.

Fifth, the company is currently profitable.

However, Moderna is a growth company with very high stock volatility, so we must pay attention to the investment scale during the investment process.

Comments

Catherine Wood's Disruptive Innovation ETF: Is ARKK worth buying?

ARKK ETF by Catherine Wood Catherine Wood's Disruptive Innovation ETF Warren Buffett is a stock god that everyone respected in the past, but in the past year, the female stock god Catherine Wood has become famous for the rising trend of technology stocks, and his head completely overshadows Buffett. Therefore, this time I want to talk to you in detail about the prestigious history of this female stock god. Catherine Wood founded ARK Investment in 2014 and listed the funds under her management under Exchange Traded Funds to facilitate investors to buy and sell, but the management fee is as low as some passive funds that track an index, about 0.75% per year. Ark Investment launched 4 ETFs in September and October 2014. The themes are Next Generation Internet, Automation Technology and Robots, Innovative Technology, and Genetics. Among them, Innovative Technology is currently the flagship ETF of Ark Investment and the most most popular ETF w...

ROKU stock forecast 2025: worth holding for a long time

1.The Roku Channel (TRC). The Roku Channel (TRC) will be a huge driving force for the company's growth. I think the market has not yet realized the huge potential of TRC. Currently, TRC is watched by 70 million people, which has doubled from last year. The growth rate is astonishing. Therefore, the ability of advertising monetization is getting stronger and stronger. ROKU mentioned in the Q1 quarterly report that if content providers promote their subscriptions in TRC, the effect will be twice as good as just on the ROKU platform. This fully shows the extremely strong marketing capabilities of TRC. The exclusive content of ROKU license Cipher has also become the most popular show in TRC, and then ROKU original packaged after the acquisition of Quibi will be launched, which will further increase the user viscosity of TRC. Roku's CEO said that the TRC flywheel has been turned, and the market seems to have not had time to digest this benefit. SVOD on the market i...

VRTX stock forecast 2025: Vertex is undervalued

Let's look at some biotech companies with stable cash flow and currently undervalued value stocks as targets for diversified portfolios. The company I shared today, called Vertex Pharmaceuticals (VRTX), is dedicated to the development of rare diseases, especially Cystic Fibrosis (CF). I have always had high respect for the rare disease group of pharmaceutical companies in the disease category. In addition, in the future, gene and cell therapies are subverting the role of rare diseases in the pharmaceutical industry, making rare diseases no longer uncommon. It's tasteless, but a field full of the future. Vertex Pharmaceuticals Inc. was established in 1989 by Joshua Boger and Kevin Kinsella. is headquartered in Boston. At that time, several very good research and development companies were established in the United States, including the aforementioned Regeneron, Gilead, and today's Vertex. Vertex In the past, he devoted himself to the development of small molecule drugs, wh...

Bear market coming, gold(GLD) assets become essential

The economic data of the global economic powers have been deteriorating, entering the bear market stage of the economy, and people have become more cautious when choosing asset investment. We should choose investment products with a low correlation coefficient with economic performance and investment products suitable for the current economic cycle. Investors should pay more attention to foreign exchange and commodity markets so that they can add value to your assets. Among many assets, anti-inflation commodities such as gold have become essential assets. Take gold as an example. For many years, gold has been regarded as an anti-inflation commodity by international capital markets and has been regarded as an important asset hedging tool by investors. There is also a saying, "The world bought gold during turbulent times." From basic political theory, we know that gold is not currency, and the currency is naturally gold and silver. Although gold has withdrawn from ...

Why has international oil(USO) prices plummeted?

As OPEC and Russia failed in negotiations and could not reach an agreement to reduce production, Saudi Arabia issued a comprehensive production increase announcement. Russia followed Saudi Arabia to increase production. Due to the sharp increase in oil supply, international oil prices plummeted, and US stocks were affected by the spread of the epidemic, and international oil prices The plunge, the U.S. stock market plummeted, triggering multiple fuses. S&P500 Index Oil is a commodity whose price is affected by supply and demand. When oil production increases, supply increases, prices fall, and at the same time affected by the epidemic, demand decreases, and prices also fall. Oil supply increases and demand decreases, which is the main cause of the plunge in international oil prices. In terms of oil supply, since the United States developed shale oil, US oil production has become the world's largest. The production cost of shale oil is more than US $ 40, which is the ...

The Federal Reserve implements interest rate hikes or cuts？

Generally speaking, the Federal Reserve implements interest rate hikes or cuts. Interest rate rises are austerity monetary policies, and interest rate cuts are a loose monetary policy. When the rate hike cycle begins, it indicates that the Federal Reserve is optimistic about the future economic outlook, economic data shows a positive outlook, and market sentiment is optimistic. To avoid excessive economic growth, the Federal Reserve has implemented austerity monetary policy and implemented interest rate hikes. When the interest rate cut cycle begins, it means that the Federal Reserve is bad on the future economic outlook, the economic data shows a bad trend, and the market is pessimistic. To stimulate economic growth, the Federal Reserve has implemented a loose monetary policy and implemented interest rate reductions. Correlation between the S & P 500 and Federal Reserve interest rates Historical data from the S & P 500 shows that when the rate hike cycle begins, the sto...

INTC stock forecast 2025: Intel's acquisition of SiFive

SiFive, a chip design start-up company based on the RISC-V instruction set architecture, has received an acquisition intention from investor Intel. A person familiar with the matter, who asked not to be named, said that Intel has offered to buy SiFive for more than $2 billion. RISC-V with x86 and Arm As we all know, Intel dominates the industry leader in x86 architecture chip technology, while SiFive focuses on open-source RISC-V technology and employs several founding members of the RISC-V architecture. For a long time, the field of CPU instruction set architecture has been dominated by x86 and Arm. Since RISC-V was born at the University of California, Berkeley in 2010, it has gradually formed a certain competitive landscape with Arm after more than ten years of development. With the gradual refinement of the application field, the model of one chip making the world has become a thing of the past. Facing the hot AI and Internet of Things market, RISC-V i...

NFLX stock forecast 2025: plummeted 22% after the earnings report.

Time to talk about Netflix, which plummeted 22% after the earnings report. First of all, Netflix's financial report this time does have its thunderous place, but part of the reason for the 22% drop in one breath is because the market sentiment has been very bad recently. At this time, the financial report thunderous will be punished more than usual. It is a wake-up call for companies that are about to report financial reports in the future, so we try to hold the stocks in the hands of companies with relatively stable historical financial reports and try to balance our positions as much as possible, to reduce the risk of financial report storms. After all, this quarter In a more dangerous period, back to the point. Let's take a look at Netflix's financial report this time. In the fourth quarter of 2021, Netflix's EPS was $1.33, exceeding analysts' estimates of $0.82, and revenue was just in line with expectations, with $7.71 billion, an increase of 16% year-on-year...

Disney stock forecast 2025: Is it time to buy now?

The much-watched Disney released its second quarter financial report this year. Benefiting from the strong recovery of theme parks and the rapid growth of streaming media business, its net profit and revenue both beat expectations. Disney's stock price rose 5% after the market. Let's take a look at the highlights of Disney's earnings this quarter. In the second quarter, Disney’s total revenue reached 17.02 billion US dollars, exceeding analysts’ expectations of 16.76 billion US dollars, a year-on-year increase of 45.5%. Net profit turned from loss to profit, from a loss of US$4.721 billion last year to a profit of US$918 million. From the perspective of departmental business, Disney Parks, Experience and Products departments have brought a boost to the company's revenue. Since the economic restart, Disney's theme parks, cruise ships and offline merchandise retail businesses have all been greatly improved. The quarterly revenue of these bu...

Bitcoin vs Ethereum vs Dogecoin: Which one is suitable to buy?

Bitcoin（BTC), Ethereum(ETH), and Dogecoin（DOGE） are the three most-watched cryptocurrencies. As a young investor, he has a strong mentality of pursuing returns and accepting new things. In recent years, cryptocurrencies have become the new favorites of many people. In particular, these three digital currencies have attracted the most attention: Bitcoin, Ethereum, and Dogecoin. However, not all cryptocurrencies are created equally and trying to determine which type is right for you can cause confusion. Each currency has advantages and disadvantages, and which currency you choose to invest in will depend on your situation. Investing in cryptocurrency must bear the risk First of all, you must consider whether cryptocurrencies are suitable for you because all cryptocurrencies are highly speculative and subject to great volatility. They have experienced the "currency disaster" in recent weeks, with an adjustable-rate of more than 30%. Fur...

FinanceLinkway

Search This Blog